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targeted (44%) disease-modifying antirheumatic drug use; 84% reported current RA 
disease activity. Additional usable data were obtained including those on education, 
employment, health insurance, income, remission state, health assessment ques-
tionnaire, and patient global for the project. CONCLUSIONS: This analysis docu-
ments the feasibility of gaining rapid and relevant responses from a representative 
community RA patient population regarding their perspective on RA remission 
through our digital direct to patient portal.
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OBJECTIVES: Patient-reported outcome instruments are used in clinical trials of 
rheumatoid arthritis (RA) treatments to evaluate treatment benefits. A growing 
body of evidence suggests that joint pain, tiredness, and morning joint stiffness 
are among the most important symptoms for RA patients. A 7-item electronic 
daily diary was developed to assess these key symptom concerns of patients 
with RA for use as efficacy endpoints in clinical trials. The aim of this study was 
to evaluate the content of the diary and to ascertain whether patients with RA 
found items in the diary interpretable and relevant through concept elicitation and 
cognitive interviews. METHODS: A cross-sectional qualitative interview study was 
conducted in adults with moderate-severe RA in the US and UK. Interviews were 
conducted using a standardized interview guide to elicit information about ways 
patients with RA experience and talk about their symptoms followed by a cognitive 
interview on the dairy. Data were analyzed utilizing a qualitative analysis software 
program, Atlas.ti. RESULTS: The study sample included 28 participants (US n= 22, 
UK n= 6; 29% male; mean age 58.41 years; RA mean duration 13.92 years). Total 
HAQ-DI mean scores were 0.84 (US) and 1.50 (UK). Morning joint stiffness (n= 19), 
joint pain (n= 28), and tiredness (n= 7) were among the most commonly experi-
enced and reported symptoms; saturation of these concepts was achieved in the 
second interview. These results demonstrated that the diary includes appropriate 
content and terminology. Cognitive interviews indicated that participants found 
the diary items and response options clear, easy to understand and relevant to 
their RA experiences. No differences in qualitative results were noted between 
the two country samples. CONCLUSIONS: Results of this qualitative study sug-
gest that the 7-item electronic daily diary includes content relevant to patients 
and is suitable for assessing RA symptoms in clinical studies of patients with 
moderate to severe RA.
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OBJECTIVES: In the past decade many studies established relationship between vita-
min D deficiency and chronic musculoskeletal pain including low back pain. Present 
study aimed to examine the effect of vitamin D3 supplementation in patients with 
chronic low back pain with low level of vitamin D. METHODS: This single arm, open 
label study was conducted in a public tertiary care teaching hospital in India after 
obtaining approval from the Ethics Review Board of the hospital. Adult patients of 
either gender, aged 18 to 65 years, with a diagnosis of CLBP and low serum 25(OH)
D3 levels (< 30 ng/mL) and not responding to medications and physical therapies, 
having a pain score of at least 50 as assessed on 0 – 100 Visual Analogue scale (VAS) 
at baseline were eligible for study recruitment. Cholecalciferol (active vitamin D3) 
in a dose of 60,000 IU/week for a period of 8 weeks was given to the enrolled sub-
jects according to standard guidelines. Study endpoints include change in pain 
score and disability as measured by modified Oswestry disability questionnaire 
(MODQ). Patient information and outcome measures were collected at baseline, 2, 
3 and 6 months. RESULTS: A total of 68 chronic low back patients were included 
in the trial. Mean baseline vitamin D level is found to be 12.80+5.73 ng/ml. After 
treatment it significantly (P< 0.01) increased to 36.07+12.51. VAS (81.03+18.57) and 
MODQ (44.83+15.47) were high at baseline. Pain intensity has significantly reduced 
to 44.71+18.96 (< 0.05) and 35.74+17.75 (< 0.05) at 3 and 6 months respectively. 
Disability has significantly reduced to 30.94+12.48 (< 0.05) and 26.10+10.03 (< 0.05) 
at 3 and 6 months respectively. CONCLUSIONS: Present study shows that vitamin 
D supplementation can improve the pain and disability in patients with CLBP. Study 
results should be carefully interpreted as it is a single arm open label study and 
concomitant medication usage was not assessed.
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OBJECTIVES: Interpretation of patient-reported outcomes (PROs) requires some defi-
nition of an important or meaningful difference. This study aimed to estimate mini-
mally important differences (MIDs) for the Patient-Reported Outcomes Measurement 
Information System (PROMIS®) Fatigue and Pain Interference scale scores in rheu-
matoid arthritis (RA). METHODS: The responsiveness of several PROs was assessed 
in an observational cohort of 521 RA patients in the Arthritis, Rheumatism and Aging 
Medical Information Systems (ARAMIS) cohorts. PROMIS Fatigue and Pain Interference 
instruments were administered at baseline, 6 months, and 12 months. Self-reported 
retrospective changes in fatigue and pain over the previous 6 months were obtained at 
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OBJECTIVES: Perioperative pain management is an important aspect of recov-
ery from TKA, as severe pain can delay ambulation and hospital discharge. The 
objective of this study was to determine the impact of local infiltration analgesia 
using LB when compared to continuous femoral nerve catheter (FNC) following 
TKA. METHODS: This study enrolled consecutive patients who received a TKA 
between April 2011 and September 2014 into three study groups, excluding bilat-
eral and revision TKA. Study Group A received adductor canal infiltration with 
bupivacaine and knee infiltration with LB. Study Group B received adductor canal 
infiltration with LB and knee infiltration with LB. The control group received a con-
tinuous FNC with an OnQ pump and ropivacaine. Numeric pain rating scores (NPRS), 
distance walked, and length of stay (LOS) were the primary outcomes. RESULTS: 
A total of 237 participants were enrolled in this study, including 98 in Group A, 34 
in Group B, and 105 controls. On postoperative day (POD) 0, mean NPRS were simi-
lar between Group A (1.8±1.7), Group B (2.7±1.8), and the control group (2.3±2.4). 
Significantly (p< 0.05) more patients in Group A (58%) and Group B (44%) walked 
on POD 0 than in the control group (0%); almost all patients walked on POD1. The 
mean distance walked was also significantly greater (p< 0.05) on POD0 and on POD1 
in Group A (33±42 feet; 193±203 feet) and Group B (42±82 feet; 211±144 feet) than 
in the control group (0 feet; 46.3±73 feet). LOS was significantly (p< 0.05) shorter in 
Group B (2.2±1.7 days), than in the control group (3.2±0.7 days) and Group A (3.0±1.7 
days). CONCLUSIONS: Local infiltration analgesia using LB improved ambulation 
and LOS following TKA when compared to continuous FNC with an OnQ pump and 
ropivacaine. The one-day decrease of hospitalization suggests an estimated cost 
savings to an Illinois hospital of $2,158 per patient.
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OBJECTIVES: Fibrodysplasia Ossificans Progressiva (FOP) is a rare and disabling 
genetic condition of progressive extraskeletal bone formation. Physical function-
ing declines as FOP progresses. The objective was to develop a measure of physical 
function (PF) in adults with FOP. METHODS: We reviewed the PROMIS PF item bank 
for relevant items for FOP, and 44 PF items were identified. We then conducted 
concept elicitation (CE) interviews in 21 patients diagnosed with FOP (with varying 
levels of disease severity) who attended the International FOP Association meeting. 
The selected PF items were administered after the CE interviews. Interview data 
were analyzed to identify categories of physical functioning that were impacted by 
FOP. Based on the CE findings and PF item data, 26 items were initially selected for 
the new measure. Clinical experts in FOP reviewed the proposed set of items. Five 
additional items were incorporated into the draft measure, and cognitive interviews 
(CIs) were conducted in 10 patients, and revisions were made to the final FOP-PF 
Questionnaire (FOP-PFQ; 28 items). RESULTS: For the CE interviews, mean age was 
30 years (range 16–54) and 58% were female. For the CIs, mean age was 31 years 
(range 16–57) and 50% were female. CE interviews demonstrated substantial impacts 
of FOP on mobility, upper extremity function, and related activities. The CE findings, 
PROMIS PF item descriptive data, and discussion with clinical experts resulted in 
31 relevant items which were included in the draft FOP-PFQ. Based on the CIs, the 
majority of patients understood the instructions, questions, and response scales; 
three items were deleted due to redundancy or item removal from the original 
PROMIS item bank. CONCLUSIONS: This qualitative research supports the content 
validity of the FOP-PFQ and illustrates the application of PROMIS item banks for 
efficient new instrument development in an ultra-rare and disabling genetic disease.
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OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune disease characterized 
by significant morbidity related to systemic and joint inflammation. With the 
availability of more targeted therapeutic approaches and the potential of disease 
remission, there is increased focus on utilizing patient reported outcomes to better 
evaluate RA treatment impact. Collecting such data efficiently, i.e., with relatively 
low cost and time expenditures, can be challenging. Our objective was to imple-
ment digital direct-to-patient methodology to collect and incorporate United States 
(US) RA patient data into the Outcome Measures in Rheumatoid Arthritis Clinical 
Trials (OMERACT) project to study the patient perspective on remission. METHODS: 
Leveraging a known community (MediGuard.org) of approximately 40,000 US RA 
patients with pre-existing consent to contact for research purposes, patients were 
contacted in December 2014 to obtain 50 responses to the OMERACT survey through 
a direct-to-patient digital communications platform. Patients did not receive any 
honoraria for survey completion. RESULTS: The first survey was completed within 
seven minutes of initial digital outreach and the fiftieth within three hours. RA 
patients from 23 continental US states were represented. Of the 50 patients, 82% 
were female, mean age 54.8 years; male patients were older, mean age 61.7 years. 
RA diagnosis duration was 11.3 years average (range 1-40). Comorbidities includ-
ing other autoimmune and musculoskeletal conditions, diabetes, cardiovascular 
disease, malignancies were reported by 70%; 76% reported synthetic (72%) and/or 
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OBJECTIVES: As pharmaceutical pipelines begin to churn out specialty products at a 
higher rate than traditional therapies, payers are experiencing double-digit growth 
in costs for biologics and other high-cost specialty drugs. Such agents are expected 
to consume half of the drug spend by 2018. Focusing on rheumatoid arthritis (RA), 
this study explored current uptake of biologics, and examined evolving payer pre-
scribing controls. METHODS: A total of 40 managed care organization (MCO) phar-
macy and medical directors, and 103 rheumatologists who prescribe biologics for 
RA were surveyed regarding prescribing and reimbursement. RESULTS: Surveyed 
rheumatologists reported that 59% of their drug-treated RA patients currently 
receive a biologic, with extensive use of Enbrel and Humira, especially, as first-line 
therapy. MCO tier coverage currently favors such TNF-α inhibitors, but surveyed 
payers indicated that, in one year’s time, newer biologics and non-TNF-α inhibitors 
that have previously been formulary-excluded will move to coverage tiers. More than 
80% of surveyed rheumatologists encounter strong-to-moderate payer control of RA 
biologics prescribing, with reports of increasing control and consequent decreased 
prescribing of specific agents. A large majority of payers confirmed using at least 
some form of restrictions, mostly prior authorization, and also step therapy and 
quantity limits. Higher copays for biologics versus other drugs are also encountered, 
and about half of payers reported a specialty pharmacy is commonly used to acquire 
biologic for RA. More than one-third of payers also reported that their contracting 
arrangements with drugmakers include rebating and price protection for RA biolog-
ics. CONCLUSIONS: As the biologics/specialty drug market for RA grows, increased 
prescribing controls by MCOs are likely. Furthermore, as competition increases, so 
will the demand for more extensive data and greater discounts/rebates to justify 
preferred coverage. Achieving preferred coverage is vital to avoid losing patient 
share to competitors achieving more favorable reimbursement terms.
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OBJECTIVES: As EU5 healthcare budgets tighten and cost-containment strategies 
become ever-more convoluted, the threat of biosimilars looms large for the rheu-
matoid arthritis (RA) biologic brands. With the first biosimilars for RA set to pen-
etrate these markets in 2015, this study explored their likely uptake as payers and 
prescribers balance clinical need with limited funds. METHODS: In September/
October 2014, 253 rheumatologists across the EU5 were surveyed regarding their 
views on biosimilars for RA, and on current and expected biologics prescribing 
patterns. In addition, 15 payers who influence reimbursement at national/regional 
level were interviewed. RESULTS: At least three-quarters of surveyed rheumatolo-
gists in each country (> 90% in Germany and Italy) plan to prescribe biosimilars of 
infliximab, etanercept, and rituximab within two years of launch, more frequently 
to new biologics patients than existing brand patients. Overall, however, in 2017, 
respondents expect less than half of their RA patients, on average, receiving any of 
these molecules to be on a biosimilar version. Interviewed payers in France, Italy, 
Spain, and the UK will encourage but not mandate biosimilar prescribing, largely 
due to anticipated modest discounts and corresponding price cuts to the brands. In 
Germany, however, payers believe that biosimilar prescribing targets and financial 
penalties for physicians who do not adhere will induce hefty discounts on bio-
similars as robust uptake will compensate. CONCLUSIONS: EU5 rheumatologists 
expect to prescribe biosimilars for RA; however, brand dominance is likely through 
2017 at least, due partly to modest discounts on the biosimilars resulting in lack of 
incentive for payers to promote their prescribing. Both prescribers and payers are 
also likely somewhat wary given the dearth of long-term RA biosimilar safety data. 
Over time, however, increasing confidence in biosimilars is probable, as are more 
aggressive payer policies encouraging prescribing across the EU5, especially as a 
favorable price-uptake ratio looks certain in Germany.
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OBJECTIVES: To identify factors associated with disease modifying antirheu-
matic drugs (DMARDs) receipt among Medicare beneficiaries enrolled in Medicare 
Advantage (MA) plans. METHODS: This study used a large nationally representa-
tive administrative claims data, supplemented by new sources of socioeconomic 
and community resource data (i.e., market source (at zip+4 levels) and area health 
resource files) in addition to CMS published contract information and Monthly 
Membership Report. The sample consisted of MA members (≥ 18 years) who were 
diagnosed with rheumatoid arthritis (RA) during 2013. The generalized linear mixed 
model was used to determine factors associated with DMARD receipt. RESULTS: A 
total of 12,835 RA patients were identified, of which 9,850 (76.74%) received DMARD. 
Factors associated with less likelihood of receiving DMARD were male gender (OR: 
0.72), increasing age (80-84 years, OR: 0.67; ≥ 85 years, OR: 0.45; vs. 18-54 years), more 
comorbidities (Charlson Comorbidity Index, OR: 0.96; HCC Risk Score, OR: 0.89), 
living in South Atlantic region compared to Mid-Atlantic (OR: 0.76), and percent 
households with 1st Individual who completed college (1-15% vs. 0%, OR: 0.82). 
Factors associated with more likelihood of DMARD receipt were Hispanic compared 
to White (OR: 1.38), use of glucocorticoids (OR: 2.22), living in New England region 
compared to Mid-Atlantic (OR: 1.82), median household income ($50,000-$74,999, 
OR: 1.31; $75,000 - $99,999, OR: 1.34; $100,000+, OR: 1.42; vs. $0-$15,000), end-stage 
renal disease (OR: 2.77), enrolled in employer group waiver plan (OR: 1.40), MA plans 
market penetration rate in service area (3-4%, OR: 1.26; 5-8%, OR: 1.45; 9-100%, OR: 
1.60; vs. 0-2%). CONCLUSIONS: The probability of receiving DMARD is correlated 
with sociodemographic, clinical, health plan and community characteristics. This 
study provides new evidence that can be used to identify subgroups of members to 
the follow-ups (a lot better/worse, a little better/worse, stayed the same). We estimated 
MIDs using the mean change in PROMIS scores for people who rated their change 
‘a little better’ or ‘a little worse.’ RESULTS: At 6 months, 41 patients reported their 
fatigue was a little better compared to baseline (mean change [SD]: -2.6 [4.8]), 119 a 
little worse (1.7 [5.6]). Pain was a little better for 60 patients (-1.9 [6.1]) and a little worse 
for 126 (0.6 [5.7]). At 12 months, fatigue was a little better compared to 6 months prior 
for 31 patients (-1.3 [6.5]) and a little worse for 133 (0.9 [5.6]). Pain was a little better 
for 53 patients (-1.8 [5.7]) and a little worse for 122 (1.5 [5.0]). Thus, the MID range 
was 1-2 points for both Fatigue and Pain Interference. Correlations between change 
scores and retrospective ratings were low (0.13-0.29), indicating that these analy-
ses may underestimate the MID. CONCLUSIONS: The MID for PROMIS Fatigue and 
PROMIS Pain Interference, estimated from this cohort of RA patients, is roughly 
2 points and corresponds to a small effect size. This is consistent with earlier 
work in this cohort demonstrating an MID of 2 points for PROMIS Physical Functioning.
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OBJECTIVES: We sought to identify whether region-specific (American Shoulder and 
Elbow Surgeon (ASES) and Disabilities of the Arm, Shoulder, and Hand (DASH)) or 
generic (EuroQOL 5D (EQ-5D) and Veterans Rand 6D (VR-6D)) patient-reported out-
comes instruments perform best in an orthopedics population with upper extremity 
morbidity (hand/wrist, elbow, or shoulder). METHODS: New patients presenting to our 
institution with complaints of upper extremity morbidity completed the ASES, DASH, 
EQ5D, and the Veterans Rand-12 (from which the VR-6D is derived). We oversampled 
patients at the initial visit to ensure adequate sample size for the six-month follow-
up. Based on standard of care, patients received conservative (e.g., casting), opera-
tive, or no treatment. Six-months after the initial appointment, patient-outcomes 
were reassessed. Performance of the instruments was examined, and compared over 
time, body parts, and treatment modality. RESULTS: A total of 294 patients provided 
responses at the first visit and six-months later. Of these patients, 21.4% reported 
to our institution for elbow morbidity, 40.5% for shoulder morbidity, and 38.1% for 
hand/wrist morbidity. The mean age of respondents was 56.5 years (hand/wrist: 57.3 
years, elbow: 52.2 years, shoulder: 57.9 years; p< 0.01). Mean initial scores were deter-
mined for the ASES: 60.9/100; DASH: 26.6/100 (reverse scored), EQ5D: 0.79/1, and VR6D: 
0.70/1. Significant differences in the initial and six-month scores were found for all 
instruments. Initial scores were poorer in the operative group for the VR6D, but the 
difference was not significant. Significant improvements were detected using the 
ASES and EQ5D, but not in the DASH or VR6D. Ceiling effects were noted for the DASH 
and EQ5D. The ASES and VR6D scores were normally distributed. CONCLUSIONS: 
We determined that a region-specific instrument, the ASES, had the most desirable 
psychometric properties in our patient population. To expand our findings, we are 
currently developing mapping algorithms between the generic preference-based and 
disease-specific measures to estimate health utilities.
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OBJECTIVES: Hip fractures are common in older people and incur substantial pain 
and suffering, disability, increased risk of death and high costs. The burden of hip 
fractures is expected to grow considerably during next years due to population 
aging. We aimed to describe the health-related quality of life (HRQoL) and the 
determinants in patients sustaining a hip fracture in Mexico. METHODS: Data 
from Mexican patients enrolled in the International Costs and Utilities Related to 
Osteoporotic Fractures Study (ICUROS) was gathered. Patients had to be diagnosed 
with a low-energy-induced hip fracture and to be at least 50 years old. HRQoL was 
prospectively collected in three phases over 12 months after fracture using the 
EQ-5D instrument. The UK preference weights were used to determine health util-
ity at different times. The accumulated HRQoL loss in the first year after fracture 
was calculated using the trapezoid method. Multivariate regression analysis was 
conducted to identify determinants of HRQoL reductions. RESULTS: 200 patients 
were evaluated. Mean (±SD) age was 77.4 ±9.9 years and 80% were women. A 15.5% 
of the sample reported a prior fracture in last 5 years; 54% had a job before fracture 
and 78% were classified into the low level of income category. Mean (95%CI) util-
ity value before fracture was 0.64 (0.59—0.68). Utility dropped to 0.01 (0.01—0.02) 
immediately after fracture and then improved to 0.46 (0.42—0.50) and 0.59 (0.55—
0.63) at month 4 and 12 post-fracture, respectively. Accumulated utility loss over 
the first year was 0.35 (0.31—0.39). HRQoL before hip fracture and age at fracture 
were the two most relevant characteristics associated with the accumulated utility 
loss. CONCLUSIONS: Hip fractures impair HRQoL in a significant way leading to 
utility values close to death shortly after fracture. Mean utility value elicited after 
one year follow-up was lower than before sustaining the fracture.
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